

From: [Giordano, Erica](#)
To: [Patel, Manisha \(manisha.patel@novartis.com\)](#)
Cc: ["Riggins, Cindy"; narin.ahmed@novartis.com](#)
Subject: BL 125646 Clinical Information Request
Date: Thursday, June 08, 2017 8:21:23 AM
Attachments: [image001.png](#)

Good morning,

Please see the information request below and provide a response by COB today and follow up by submitting the information as an official amendment to the BLA.

Please provide the number of enrolled subjects who either received or were to receive product manufactured in New Jersey versus Germany. This should be as of the last data cut-off for the BLA.

Please confirm receipt of this request.

Thank you,

Erica Giordano

Regulatory Project Manager

Center for Biologics Evaluation and Research

Office of Tissues and Advanced Therapies

U.S. Food and Drug Administration

Tel: 240-402-8298

Erica.Giordano@fda.hhs.gov



"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone."